



UHID/MR No : CINR.0000157440 Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884

 Collected
 : 05/Oct/2023 08:29AM

 Received
 : 05/Oct/2023 01:32PM

 Reported
 : 05/Oct/2023 07:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

			<u> </u>	
ARCOFEMI - MEDIWHEEL - FULL B	ODY ANNUAL PLUS	S ABOVE 50Y M	ALF - 2D FCHO - PAN	INDIA - FY2324
,		-		
Test Name	Result	Unit	Bio. Ref. Range	Method

HEMOGRAM, WHOLE BLOOD EDTA				
HAEMOGLOBIN	14.7	g/dL	13-17	Spectrophotometer
PCV	44.10	%	40-50	Electronic pulse & Calculation
RBC COUNT	5.01	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	87.9	fL	83-101	Calculated
MCH	29.3	pg	27-32	Calculated
MCHC	33.3	g/dL	31.5-34.5	Calculated
R.D.W	13.1	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,470	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	LC)			
NEUTROPHILS	60.6	%	40-80	Electrical Impedance
LYMPHOCYTES	28	%	20-40	Electrical Impedance
EOSINOPHILS	1.5	%	1-6	Electrical Impedance
MONOCYTES	9.8	%	2-10	Electrical Impedance
BASOPHILS	0.1	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5738.82	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2651.6	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	142.05	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	928.06	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	9.47	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	284000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	8	mm at the end of 1 hour	0-15	Modified Westegren method
PERIPHERAL SMEAR		OI I HOUF		method

ERYTHROCYTES: are predominantly normocytic normochromic, no inclusions/hemoparasites seen.

LEUCOCYTES: are normal in number, morphology and distribution.

PLATELETS: are adequate in number, seen discretely and show normal morphology.

IMPRESSION: Normocytic normochromic blood picture.

Page 1 of 13







: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No Visit ID

: CINR.0000157440

Ref Doctor

: CINROPV206998

: Dr.SELF Emp/Auth/TPA ID : 9742819884 Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 01:32PM

Reported

Status

: 05/Oct/2023 07:19PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY


ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL	PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324
-----------------------------------------	----------------------------------------------------

Test Name Result Unit Bio. Ref. Range Method

Kindly correlate clinically.

Page 2 of 13









: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No Visit ID : CINR.0000157440

Ref Doctor

: CINROPV206998 : Dr.SELF

Emp/Auth/TPA ID : 9742819884

Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 01:32PM

Reported

: 05/Oct/2023 06:54PM

: Final Report

Status Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL B	ODY ANNUAL PLUS	S ABOVE 50Y M	ALE - 2D ECHO - PAN	NDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR, I	WHOLE BLOOD EDT	4	
BLOOD GROUP TYPE	В		Microplate Hemagglutination
Rh TYPE	Positive		Microplate Hemagglutination

Page 3 of 13





Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)





Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884 Collected : 05/Oct/2023 08:29AM
Received : 05/Oct/2023 01:07PM
Reported : 05/Oct/2023 03:03PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL B	ODY ANNUAL PLUS	S ABOVE 50Y M	ALE - 2D ECHO - PAN	INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GLUCOSE, FASTING , NAF PLASMA	107	mg/dL	70-100	HEXOKINASE	
-------------------------------	-----	-------	--------	------------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.

2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2	84	mg/dL	70-140	HEXOKINASE
HOURS, SODIUM FLUORIDE PLASMA (2				
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.8	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	120	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

	,
REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4

Page 4 of 13







Patient Name : Mr.VIJAYAKUMAR S

Age/Gender : 44 Y 1 M 15 D/M

UHID/MR No : CINR.0000157440

Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884 Collected : 05/Oct/2023 08:29AM

Received : 05/Oct/2023 01:07PM Reported : 05/Oct/2023 03:03PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
- Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13









Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884

 Collected
 : 05/Oct/2023 08:29AM

 Received
 : 05/Oct/2023 11:56AM

 Reported
 : 05/Oct/2023 12:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

DEL ARTHER OF BIOGRAMMOTICS					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	241	mg/dL	<200	CHO-POD
TRIGLYCERIDES	127	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	196	mg/dL	<130	Calculated
LDL CHOLESTEROL	170.5	mg/dL	<100	Calculated
VLDL CHOLESTEROL	25.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	5.35		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- 4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13

SIN No:SE04501936





Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884 Collected : 05/Oct/2023 08:29AM
Received : 05/Oct/2023 11:56AM
Reported : 05/Oct/2023 12:52PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

	2 = 1 7				
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.85	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.13	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.72	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	15	U/L	<50	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	21.0	U/L	<50	IFCC
ALKALINE PHOSPHATASE	71.00	U/L	30-120	IFCC
PROTEIN, TOTAL	6.59	g/dL	6.6-8.3	Biuret
ALBUMIN	4.45	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.14	g/dL	2.0-3.5	Calculated
A/G RATIO	2.08		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.
- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

${\bf 3. \ Synthetic \ function \ impairment:}$

- · Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13



SIN No:SE04501936





: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No Visit ID

: CINR.0000157440 : CINROPV206998

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 9742819884 Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 11:56AM

Reported Status

: 05/Oct/2023 12:52PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL B	ODY ANNUAL PLUS	S ABOVE 50Y M	IALE - 2D ECHO - PAN	INDIA - FY2324	
Test Name	Result	Unit	Bio. Ref. Range	Method	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.88	mg/dL	0.72 – 1.18	JAFFE METHOD	
UREA	19.60	mg/dL	17-43	GLDH, Kinetic Assay	
BLOOD UREA NITROGEN	9.2	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	6.35	mg/dL	3.5–7.2	Uricase PAP	
CALCIUM	9.20	mg/dL	8.8-10.6	Arsenazo III	
PHOSPHORUS, INORGANIC	2.92	mg/dL	2.5-4.5	Phosphomolybdate Complex	
SODIUM	135	mmol/L	136–146	ISE (Indirect)	
POTASSIUM	3.9	mmol/L	3.5–5.1	ISE (Indirect)	
CHLORIDE	101	mmol/L	101–109	ISE (Indirect)	

Page 8 of 13









: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No Visit ID : CINR.0000157440

Ref Doctor

: CINROPV206998

Emp/Auth/TPA ID

: Dr.SELF : 9742819884 Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 11:56AM

Reported Status : 05/Oct/2023 12:52PM : Final Report

Sponsor Name


: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	25.00	U/L	<55	IFCC
(GGT) , SERUM				

Page 9 of 13



Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)







Patient Name : Mr.VIJAYAKUMAR S Age/Gender : 44 Y 1 M 15 D/M

UHID/MR No : CINR.0000157440 Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884 Collected : 05/Oct/2023 08:29AM Received : 05/Oct/2023 11:55AM

Reported : 05/Oct/2023 01:04PM

: Final Report Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

Status

DELYNTHIEN OF HIMMONOCOU					
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

THYROID PROFILE TOTAL (T3, T4, TSH),	SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	0.84	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	6.58	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	2.099	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 13



SIN No:SPL23141784





: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No

: CINR.0000157440

Visit ID

: CINROPV206998

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 9742819884

Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 11:55AM

Reported

Status

: 05/Oct/2023 12:51PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL!	PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324
------------------------------------------	----------------------------------------------------

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

TOTAL PROSTATIC SPECIFIC ANTIGEN	0.420	ng/mL	0-4	CLIA	
(tPSA), SERUM					

Page 11 of 13









Patient Name : Mr.VIJAYAKUMAR S Age/Gender : 44 Y 1 M 15 D/M

UHID/MR No : CINR.0000157440 Visit ID : CINROPV206998

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9742819884

 Collected
 : 05/Oct/2023 08:29AM

 Received
 : 05/Oct/2023 12:38PM

 Reported
 : 05/Oct/2023 01:31PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	6.0		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.025		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	POSITIVE +		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	DUNT AND MICROSCOPY			
PUS CELLS	2-3	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13



SIN No:UR2196249





: Mr.VIJAYAKUMAR S

Age/Gender

: 44 Y 1 M 15 D/M

UHID/MR No

: CINR.0000157440

Visit ID Ref Doctor : CINROPV206998

Emp/Auth/TPA ID

: Dr.SELF : 9742819884 Collected

: 05/Oct/2023 08:29AM

Received

: 05/Oct/2023 12:38PM

Reported

Status

: 05/Oct/2023 02:10PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLU	S ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method

URINE GLUCOSE(POST PRANDIAL) **NEGATIVE**

NEGATIVE

Dipstick

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY M.B.B.S, M.D (Biochemistry) CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S, M.D(Pathology)

Consultant Pathologist

Dr PRASANNA B.K.P Md.Path.Pathologist

Page 13 of 13



Patient Name : Mr. Vijayakumar S Age/Gender : 44 Y/M

UHID/MR No. : CINR

: CINR.0000157440

Sample Collected on

LRN# : RAD2116805

Ref Doctor : SELF **Emp/Auth/TPA ID** : 9742819884 OP Visit No Reported on : CINROPV206998

Specimen

: 05-10-2023 19:44

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Bilateral lung fields appear normal.

Bilateral hila appears normal.

Bilateral CP angle appear normal.

IMPRESSION:

Mild cardiomegaly.



Dr. SUJIT MAHESWARI

MBBS, MD

RADIOLOGY



Patient Name: Mr. Vijayakumar SAge/Gender: 44 Y/M

 UHID/MR No.
 : CINR.0000157440
 OP Visit No
 : CINROPV206998

 Sample Collected on
 : 05-10-2023 11:14

Ref Doctor : SELF

Emp/Auth/TPA ID : 9742819884

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified. No evidence of intra/extrahepatic biliary tree dilatation noted. Portal vein appears to be of normal size.

GALLBLADDER: Moderately distended. No definite calculi identified. No evidence of abnormal wall thickening noted.

SPLEEN: Appears normal in size, shape and echopattern. No focal parenchymal lesions identified.

PANCREAS: Obscured by bowel gas. However, the visualized portion appear normal.

KIDNEYS: Both kidneys appear normal in size, shape and echopattern. Corticomedullary differentiation appears maintained. No evidence of calculi or hydronephrosis on either side.

Right kidney measures 10.2x4.9cm.

Left kidney measures 10.0x5.4cm.

URINARY BLADDER: Distended and appears normal. No evidence of abnormal wall thickening noted.

PROSTATE: Prostate is normal in size and echo-pattern.

No free fluid is seen.

IMPRESSION:

NO SIGNIFICANT SONOGRAPHIC ABNORMALITY DETECTED.

Dr. RAMESH G
MBBS DMRD
RADIOLOGY